Baicalin prevents fibrosis of human trabecular meshwork cells via inhibiting the MyD88/NF-κB pathway

Li, Li; Liu, Qian; Shi, Lijuan; Zhou, Xibin; Wu, Wei; Wang, Xue; Wang, Lihua; Wu, Zhihong

doi:10.1016/j.ejphar.2022.175425

Cited by 6 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NF-κB activation is required in HTLV-1 infection and ocular hypertension. NF-kB is also important for the fibrosis of human TM [ 46 , 47 ]. According to our previous studies, HTLV-1 infection induced phosphor-p65 NF-κB expression and ultimately improved the inflammation of hTM cells [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Yang,

Kamoi,

Zong

et al. 2024

IJMS

View full text Add to dashboard Cite

Human T-cell leukemia virus type 1 (HTLV-1), a virus that affects 5–10 million people globally, causes several diseases, including adult T-cell leukemia-lymphoma and HTLV-1-associated uveitis (HU). HU is prevalent in Japan and often leads to secondary glaucoma, which is a serious complication. We investigated the efficacy of ripasudil, a Rho-associated coiled coil-forming protein kinase inhibitor, in alleviating changes in human trabecular meshwork cells (hTM cells) infected with HTLV-1. HTLV-1-infected hTM cells were modeled in vitro using MT-2 cells, followed by treatment with varying concentrations of ripasudil. We assessed changes in cell morphology, viability, and inflammatory cytokine levels, as well as NF-κB activation. The results showed that ripasudil treatment changed the cell morphology, reduced the distribution of F-actin and fibronectin, and decreased the levels of certain inflammatory cytokines, such as interleukin (IL)-6, IL-8, and IL-12. However, ripasudil did not significantly affect NF-κB activation or overall cell viability. These findings suggest that ripasudil has the potential to treat secondary glaucoma in patients with HU by modulating cytoskeletal organization and alleviating inflammation in HTLV-1-infected hTM cells. This study lays the foundation for further clinical studies exploring the effectiveness of ripasudil for the treatment of secondary glaucoma associated with HU.

show abstract

Section: Discussionmentioning

confidence: 99%

Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Yang,

Kamoi,

Zong

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…A recent study conducted on human TM cells found that baicalin, an extract from Scutellaria baicalensis Georgi , has the potential to prevent fibrosis by reducing the deposition of the TGF-β2-induced extracellular matrix. This effect was achieved through the modulation of the NF-kB pathway [ 174 ]. Another study utilizing an experimental mouse model of glaucoma characterized by the transgenic inhibition of astroglial NF-kB, demonstrated a protective effect against neurodegeneration in RGC axons and somas.…”

Section: Emerging Curative Strategies: Immunomodulatory and Antioxidantsmentioning

confidence: 99%

Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment

Buonfiglio,

Pfeiffer,

Gericke

2023

Pharmaceuticals

View full text Add to dashboard Cite

Glaucoma, a group of diseases characterized by progressive retinal ganglion cell loss, cupping of the optic disc, and a typical pattern of visual field defects, is a leading cause of severe visual impairment and blindness worldwide. Elevated intraocular pressure (IOP) is the leading risk factor for glaucoma development. However, glaucoma can also develop at normal pressure levels. An increased susceptibility of retinal ganglion cells to IOP, systemic vascular dysregulation, endothelial dysfunction, and autoimmune imbalances have been suggested as playing a role in the pathophysiology of normal-tension glaucoma. Since inflammation and oxidative stress play a role in all forms of glaucoma, the goal of this review article is to present an overview of the inflammatory and pro-oxidant mechanisms in the pathophysiology of glaucoma and to discuss immunomodulatory and antioxidant treatment approaches.

show abstract

“…Baicalin, the major bioactive compound isolated from Scutellaria radix , has been explored to possess multiple biological effects, such as anti-inflammatory, antioxidant, anticancer and antimicrobial properties ( Ganguly et al, 2022 ). This pharmacological agent can inhibit TGF-β2-induced ECM expression by repressing MyD88/NF-κB signaling pathway in hTM cell ( Li et al, 2023 ), showing that baicalin can be regarded as a potential candidate for glaucoma treatment.…”

Section: Plant-derived Productsmentioning

confidence: 99%

“… RU 38486 glucocorticoid receptor antagonist human TM cell ( Li et al, 2002 ) Decreasing fibronectin level in ECM of the cells. Plant-derived products Agent Dosage Cell line/tissue Efficiency and Potency against fibrosis baicalin 20 μM human TM cell ( Li et al, 2023 ) Inhibiting TGF-β2-induced ECM expression by repressing MyD88/NF-κB signaling pathway. astragaloside IV 50 and 100 μM human TM cell ( Kasetti et al, 2021 ) Decreasing extracellular matrix and α-SMA deposition as well as enhancing the levels and enzymatic activities of matrix metalloproteinases.…”

Section: Introductionmentioning

confidence: 99%